Otezla Tablet, Film Coated
Product Images NDC 55513-137

15 FDA label images from Amgen, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Otezla (NDC 55513-137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Otezla 01)

Chemical Structure (Otezla 01)
Chemical structure of apremilast, the active ingredient in Otezla, depicted as a 2D molecular diagram showing the arrangement of atoms and bonds within the molecule.*
FDA Label Image

Figure 1 (Otezla 02)

Figure 1 (Otezla 02)
Line graph showing the proportion of subjects with whole body itch NRS response over 16 weeks comparing Otezla 30 mg twice daily and placebo. The vertical axis represents percentage response, and the horizontal axis represents time in weeks. The Otezla 30 mg group shows a higher and increasing proportion of subjects responding compared to placebo.*
FDA Label Image

Figure 2 (Otezla 03)

Figure 2 (Otezla 03)
A line graph comparing the proportion of subjects with scalp itch NRS response (%) over 16 weeks between placebo and Otezla 30 mg twice daily. The graph shows higher response rates for Otezla than placebo throughout the study period, with time in weeks on the x-axis and response proportion on the y-axis.*
FDA Label Image

Figure 3 (Otezla 04)

Figure 3 (Otezla 04)
A line graph comparing the mean number of oral ulcers over 12 weeks between placebo and OTEZLA 30 mg taken twice daily. The graph shows a decrease in oral ulcers for OTEZLA compared to placebo, with data points at multiple time intervals (0, 1, 2, 4, 6, 8, 10, and 12 weeks). Error bars indicate variability in the data.*
FDA Label Image

Figure 4 (Otezla 05)

Figure 4 (Otezla 05)
A line chart comparing mean oral ulcer pain over 12 weeks between placebo and Otezla 30 mg twice daily. The y-axis represents mean oral ulcer pain, and the x-axis represents time in weeks. The Otezla treatment group shows a notable decrease in pain compared to the placebo group.*
FDA Label Image

Principal Display Panel (60 Tablet Bottle Label)

Principal Display Panel (60 Tablet Bottle Label)
Otezla 30 mg tablets packaging label showing the brand name, generic name apremilast, and a count of 28 tablets. The label includes the Amgen logo, NDC 55513-137-28, and indicates the product is prescription only.*
FDA Label Image

Principal Display Panel (28 Day Treatment Initiation Pack)

Principal Display Panel (28 Day Treatment Initiation Pack)
Otezla 30 mg tablets packaging label showing the brand name, generic name apremilast, and dosage strength of 30 mg. The label indicates a package containing 60 tablets, manufactured for Amgen Inc. Instructions include storing below 30°C and directions to see full prescribing information for dosage and administration. The label also features the Amgen logo and states the product is made in Switzerland.*
FDA Label Image

Principal Display Panel (14 Day Treatment Initiation Pack)

Principal Display Panel (14 Day Treatment Initiation Pack)
Otezla 30 mg (apremilast) tablets label, a prescription drug manufactured by Amgen, Inc. The label indicates 500 tablets in the package and instructs storage below 30°C (86°F). It includes directions to see full prescribing information for dosage and administration. The label also has the Amgen logo, barcode, and patent URL.*
FDA Label Image

Principal Display Panel (14 Day Treatment Initiation Pack)

Principal Display Panel (14 Day Treatment Initiation Pack)
Otezla (apremilast) tablets 28 Day Starter Pack packaging label. The label shows it contains 55 tablets in various strengths for titration: 10 mg, 20 mg, and 30 mg tablets. The product is a prescription drug labeled by Amgen, Inc.*
FDA Label Image

Principal Display Panel (60 Tablet Bottle Label)

Principal Display Panel (60 Tablet Bottle Label)
Otezla (apremilast) tablets Starter Pack kit by Amgen, Inc. The packaging indicates it is a sample starter pack for titration over 5 days up to the prescribed dose of 30 mg, containing 27 tablets: four 10 mg, four 20 mg, and nineteen 30 mg tablets. The label includes the NDC 55513-485-95 and states Rx Only.*
FDA Label Image

Principal Display Panel (28 Day Treatment Initiation Pack)

Principal Display Panel (28 Day Treatment Initiation Pack)
Otezla Starter Pack sample packaging label for apremilast tablets from Amgen, Inc. The label specifies a titration pack containing 10 mg, 20 mg, and 30 mg tablets for a 5-day dosage escalation to 30 mg, with a total of 27 tablets in each pack. It is marked for prescription use and sample distribution only.*
FDA Label Image

Principal Display Panel (14 Day Treatment Initiation Pack)

Principal Display Panel (14 Day Treatment Initiation Pack)
Packaging label for Otezla 14 Day Treatment Initiation Pack containing apremilast tablets. The label indicates it is a sample not for sale and includes instructions for titration over 3 days up to a prescribed dose of 20 mg, listing quantities of 10 mg and 20 mg tablets. Manufactured by Amgen, Inc.*
FDA Label Image

Principal Display Panel (14 Day Treatment Initiation Pack)

Principal Display Panel (14 Day Treatment Initiation Pack)
Otezla (apremilast) tablets 10 mg and 20 mg, 14 Day Treatment Initiation Pack by Amgen, Inc. This kit includes 27 tablets: four 10 mg and twenty-three 20 mg tablets for dose titration. Label displays dosing instructions, storage information, manufacturer details, and a QR code for additional support.*
FDA Label Image

Principal Display Panel (75 mg Tablet Bottle Label)

Principal Display Panel (75 mg Tablet Bottle Label)
Label for Otezla XR 75 mg extended-release tablets, an oral prescription drug containing apremilast. The label indicates it is a once-daily dosage with a quantity of 30 tablets per package. Manufactured by Amgen, Inc., the label includes storage instructions and trademark information. The product is made in Switzerland.*
FDA Label Image

Principal Display Panel (28 Day Treatment Initiation Pack)

Principal Display Panel (28 Day Treatment Initiation Pack)
Otezla 28 Day Treatment Initiation Pack by Amgen, Inc, featuring apremilast tablets in strengths of 10 mg, 20 mg, 30 mg, and Otezla XR 75 mg extended-release tablets. The kit contains 41 tablets total, including various quantities of each strength designed for dose titration and transition. The label highlights a 28-day treatment supply.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.